Psyence Biomedical (PBM) Non-Current Assets (2024 - 2025)
Psyence Biomedical (PBM) recorded quarterly Non-Current Assets of $5.2 million in Q3 2025, up 585.19% quarter-over-quarter from $756096.0 in Q1 2025, and up 51062.26% on a YoY basis from N/an in Q3 2024.
Psyence Biomedical (PBM) Non-Current Assets (2024 - 2025) Analysis & Trends
Psyence Biomedical's Non-Current Assets history runs 2 years deep, the most recent figure standing at $5.2 million for Q3 2025.
- In Q3 2025, Non-Current Assets rose 51062.26% year-over-year to $5.2 million; the TTM figure through Sep 2025 stood at $6.0 million (changed N/A YoY), while the FY2025 annual figure was $756096.0, up 13679.77% from the prior year.
- Non-Current Assets was $5.2 million for Q3 2025 at Psyence Biomedical, up from $756096.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $5.2 million in Q3 2025 to a low of $5487.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 62,953.78 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 39.71 Mn |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | 22.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.18 Mn |
| Mar 31, 2025 | 756,096.00 |
| Sep 30, 2024 | 10,126.00 |
| Mar 31, 2024 | 5,487.00 |